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Drug desensitization is the induction, within hours to days, of a temporary state of tolerance to a drug which the patient has 
developed a hypersensitivity reaction to. It may be used for IgE and non-IgE mediated allergic reactions, and certain non-allergic 
reactions. The indication for desensitization is where no alternative medications are available for the treatment of that condition, and 
where the benefits of desensitization outweigh the risks. Desensitization is a therapeutic modality for drug allergy (similar to allergen 
specific immunotherapy for allergic rhinitis and insect venom anaphylaxis). In contrast, the drug provocation test is a diagnostic 
modality used to confirm or refute the diagnosis of drug allergy. This review discusses the clinical applications of desensitization for 
the treatment of common infectious, metabolic and cardiovascular diseases, and oncological conditions in the Asia-Pacific region.
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INTRODUCTION
Although many classes of drugs are presently available to treat 
various medical conditions, certain drugs with the potential to 
cause allergic or non-allergic drug hypersensitivity reactions [1] 
may be the therapeutic drug of choice as no better alternatives 
are available. Examples of drugs with a propensity to cause 
drug allergy include isoniazid, rifampicin and pyrazinamide 
for the first-line treatment of tuberculosis (TB); allopurinol 
for the treatment of tophaceous gout, and trimethoprim-
sulfamethoxazole (TMP-SMX) for the treatment and prophylaxis 
of Pneumocystis jiroveci infection and toxoplasmosis in human 
immunodeficiency virus (HIV) infected patients [2, 3]. As for 
drugs causing non-allergic drug hypersensitivity, aspirin remains 
an important anti-platelet agent in those with cardiovascular 
diseases, in particular individuals with coronary artery disease 
following percutaneous coronary intervention to prevent in-
stent thrombosis.
Drug desensitization is the induction, within hours to days, 
of a temporary state of tolerance to a drug which the patient 
has developed a hypersensitivity reaction to [4]. Although 
in the strictest sense, this term/procedure should only be 
applied to tolerance induction in IgE-mediated allergic drug 
hypersensitivity, it is now also used in tolerance induction 
for non-IgE mediated allergic reactions (e.g. non-immediate 
reactions like maculopapular exanthema and fixed drug apallergy.org
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eruptions), and non-allergic reactions (e.g. aspirin intolerance or 
hypersensitivity). The indication for drug desensitization is where 
no better alternative medications are available for treatment 
of that condition, and where the benefits of desensitization 
outweigh the risks. Desensitization is a therapeutic modality for 
probable or definite drug allergy based on the results of validated 
allergological tests or drug imputability (similar to specific 
immunotherapy for allergic rhinitis and insect venom anaphylaxis) 
[5]. In contrast, the drug provocation test is a diagnostic modality 
used to confirm or refute the diagnosis of drug allergy [6].
Mechanisms in drug desensitization
Various studies have proposed different mechanisms for IgE-
mediated desensitization: internalization of antigen/IgE/ FCεRI 
and cross-linking of inhibitory receptors on mast cells [7]; reduced 
levels of up-stream signal transducing molecules, such as Syk 
which are necessary for activation and mast cell IgE-signalling 
[8]; negative regulation of IgE mediated allergic responses by 
Lyn kinase in mast cell responses both in vivo and in vitro [9]; and 
elevated levels of the signal transducer and transcriptor activator 
STAT-6 involved in transcription of IL-4 and IL-13 necessary for 
desensitization of murine mast cells [10, 11]. 
The mechanism for desensitization in non-immediate reactions 
remains unknown. This is because of the many mechanisms 
involved in non-immediate reactions prior to T cell activation, 
including haptenation, biotransformation of inert prohaptens 
to reactive haptens [12], and direct interaction of non-haptens 
with T-cell receptors [13]. For instance, interference with SMX 
haptenation, but not SMX-specific antibodies, appear to be 
important in the development of clinical sensitivity (i.e. failure of 
desensitization) in patients with AIDS who have undergone SMX 
desensitization [14].
 At the site of the target organ, CD25+CD4+ T 
regulatory cells in the epidermis of lesions
 of fixed drug eruptions 
(FDE) appear to be important in the induction of desensitization 
to allopurinol FDE [15].
In non-allergic drug hypersensitivity reactions like acetylsalicylic 
acid (ASA) or aspirin intolerance, abnormal metabolism of 
arachidonic acid results in a decrease in the levels of the anti-
inflammatory prostaglandins, especially prostaglandin E2, and 
an increase in the synthesis of cysteinyl leukotrienes, particularly 
leukotrienes C4, D4 and E4. The excessive production of 
leukotrienes results in urticaria, angioedema, bronchospasm and 
occasionally non-allergic anaphylactic (anaphylactoid) reactions in 
such pre-disposed individuals [16]. These patients often develop 
aspirin exacerbated respiratory disease (AERD) which comprises 
aspirin intolerant asthma with chronic rhinosinusitis and/or nasal 
polyposis, or aspirin induced urticaria (AIU)/ aspirin-exacerbated 
chronic urticaria [17, 18]. High dose aspirin desensitization (650-
1,300 mg/day) has been shown to ameliorate AERD symptoms 
through various postulated mechanisms including direct 
mast cell inhibition [19], direct modulation of the intracellular 
biochemical pathways of inflammatory cells, reduced production 
of thromboxane A2, reduced leukotriene B4 levels [20], increased 
LTE4 levels [21], inhibition of activation of transcription factors 
like NFκB [22], and inhibition of IL-4 and IL-13 induced activation 
of STAT6 [23]. During acute desensitization in AERD, significant 
elevation in exhaled nitric oxide and serum tryptase levels have 
been demonstrated; in long term treatment with ASA, IL-4 is 
suppressed, the pro-inflammatory matrix metalloproteinase-9 is 
down-regulated, while the TH1 marker FMS-like tyrosine kinase 3 
ligand increases [24].
 It is likely that a similar mechanism exists in 
patients with coronary artery disease successfully desensitized to 
low-dose (81-325 mg/day) aspirin [24-26]. 
Principles in drug desensitization
Several cardinal principles in drug desensitization [4, 5, 27] for 
drug allergy/hypersensitivity are as follows:
•	 	 There is no alternative drug available for the treatment of the 
underlying condition (e.g. allopurinol in chronic tophaceous 
gout, penicillin in pregnant women with syphilis, platinum 
salts in recurrent ovarian cancer).
•	 	 The drugs for the treatment of the underlying condition are 
superior to the alternatives (e.g. isoniazid for tuberculosis).
•	 	 The initial reaction should not be potentially life-threatening 
reaction. Drug induced hypersensitivity syndrome (DiHS), 
Stevens Johnson syndrome (SJS), toxic epidermal necrolysis 
(TEN) are absolute contraindications to desensitization. 
However, anaphylaxis is not a contraindication.
•	 	 The benefits of desensitization outweigh the risks of 
recurrence of drug hypersensitivity/ allergy.
•	 	 Starting doses are at 1:1,000,000 to 1:100 of the target 
therapeutic dose depending on the severity of the initial 
reaction, or based on end-point intradermal skin testing to a 
non-irritative concentration of the drug.
•	 	 Dose escalations are doubled at 15-30 min intervals for 
immediate reactions, or at intervals of up to 24 h for non-
immediate reactions.
•	 	 Close monitoring and resuscitative equipment with staff apallergy.org
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trained in resuscitation should be available for rapid 
desensitization.
•	 	 Pre-medications with systemic corticosteroids or anti-
histamines should be avoided.
•	 	 Concomitant medical conditions should be stable (e.g. 
asthma, cardiac insufficiency).
•	   The patient is still deemed allergic to the drug to which he/
she has been successfully desensitized.
•	 	 The patient must adhere to the drug daily in order for 
tolerance to be maintained, unless breakthrough reactions 
occur where dose escalations may need to be interrupted/ 
slowed down.
•	 	 In desensitization for non-immediate reactions, periodic 
monitoring of complete blood count and liver enzymes 
should be considered prior to interval dose escalations.
The European Academy of Allergy and Clinical Immunology 
[4] has recently drawn up guidelines on desensitization in 
drug allergy. The American Academy of Allergy Asthma and 
Immunology and the American College of Allergy Asthma and 
Immunology have also addressed the topic of desensitization 
or “temporary induction of drug tolerance” in its recent 2010 
Updated Practice Parameter on Drug Allergy [27]. Both academies 
are in the midst of establishing databases of desensitization 
protocols for which sufficient evidence for the effectiveness/ 
adverse events for each protocol exists.
In this review, we will focus on drugs for which desensitization 
protocols have been described for 4 major classes of diseases 
highly prevalent in the Asia-Pacific region: infectious, metabolic, 
cardiovascular diseases and oncological conditions.
Desensitization for betalactam allergy
Betalactams are the most common cause of drug allergies 
in most prospective epidemiological studies on adverse drug 
reactions/drug allergies [28-32] including studies originating 
from the Asia-Pacific region [33, 34]. The majority of the studies 
on betalactam desensitization to date have been in patients 
with cystic fibrosis who require anti-microbial therapy, of 
which betalactams are the antibiotics of choice [35, 36]. Rapid 
desensitization protocols using oral [37] and intravenous 
penicillins, cephalosporins [38] (ceftriaxone, cefepime [39], 
ceftazidime [40], cefotaxime [41], and cefazolin [42]) have 
been described and in general found to be effective and safe. 
Successful desensitization protocols to the carbapenems 
including meropenem [43] and imipenem/cilastatin [44] have 
also been well-described with no adverse reactions, even when 
used in patients with renal impairment [45].
 Adverse effects where 
they occur, are usually mild comprising flushing, pruritis, rash or 
urticaria, with no serious reactions or late reactions in most studies 
[46].
Anti-tuberculous drug desensitization
Mycobacterium tuberculosis infection remains endemic in 
certain parts of Asia, with one-third of the world’s burden of 
TB, or about 4.9 million prevalent cases, found in the World 
Health Organization South-East Asia Region [47].
 Treatment of 
TB infection involves combinations of anti-tuberculous drugs 
including isoniazid, rifampicin, ethambutol and pyrazinamide. 
Non-immediate reactions to anti-tuberculous drugs are much 
more common than immediate reactions, with hypersensitivity 
reactions that lead to discontinuance of antituberculous agents 
and to switch of therapy seen in 4-5% of the general population 
[48]. Drug eruptions in the form of maculopapular eruptions 
(MPE), lichenoid drug eruptions [49], haematological reactions, 
hepatitis, DiHS, SJS/TEN [50] have all been reported in the 
literature [51]. In practice, it is often difficult to determine which of 
the anti-tuberculous drugs resulted in the allergic drug reaction. 
Although patch tests and lymphocyte transformation tests would 
be useful in such situations to help identify the putative drug, 
these tests are not readily available in the Asia-Pacific region, are 
often drug- and reaction-specific (hence negative tests may not 
be useful), and it is usually not possible to defer TB treatment for 
4-6 weeks pending the outcome of results of these tests [52-55]. 
Drug provocation tests although useful in helping to determine 
the putative drug, are not without risks especially in DiHS, SJS and 
TEN. Second-line drugs like fluoroquinolones, aminoglycosides, 
cycloserine and clofazamine, are not encouraged as alternative 
therapy for patients with drug allergy to first-line TB drugs as 
they are usually reserved for multi-drug-resistant (MDR)-TB [56]. 
Even though MDR-TB although only occurs in fewer than 3% 
of new cases and 18% of re-treatment cases in the south-east 
Asia region, this still translates to significant absolute numbers 
of patients [47]. As such, rapid oral desensitization regimes have 
been described for streptomycin [57], isoniazid [58], rifampicin 
[58-60], ethambutol [60], and para-amniosalicylic acid [61]. These 
regimes often involve reintroducing the anti-tuberculous drugs 
as soon as the allergic reaction has settled. In addition, more 
than one drug often needs to be reintroduced, reaching target apallergy.org
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dose within 3 days, with at most a 3-5 day interval apart, because 
leaving patients on anti-tuberculous monotherapy increases 
the risk of emergence of drug-resistant tuberculosis. If the initial 
allergic reaction was SJS/TEN, the risks of desensitization versus 
the benefits would need to be considered very carefully in 
consultation with the patient, the attending infectious diseases 
physician or pulmonologist. Most of the published literature on 
oral desensitization to TB drug therapies in the Asia-Pacific region 
originates from Japan [61, 62] and Korea [63]. In a series which 
followed desensitization guidelines of the Japanese Society of 
Tuberculosis [62], adverse reactions among 19 patients aged 
23-88 years old, included drug eruption (42.1%), drug fever 
(36.8%), drug fever with drug eruption (15.8%), and drug fever 
with cervical lymphadenopathy (15.8%). The clinical effect of 
desensitization therapy for these antituberculous drugs was 
good in 14/17 (82%) cases for rifampicin, and 6/8 (75%) cases 
for isoniazid. In another case report from Korea, a child with 
tuberculous osteomyelitis of the ankle who developed fever, 
pruritis and hepatitis 3 days after isoniazid, rifampin, kanamycin 
and pyrazinamide, was successfully desensitized to rifampin, 
isoniazid and ethambutol with oral steroid and cetirizine after 
recurrence of skin rash, facial flushing, chest discomfort during 
the initial desensitization process. She successfully completed the 
standard isoniazid (10 mg/kg) and rifampin (12 mg/kg) regimens 
for 18 months without adverse reactions [63]. 
Desensitization in human immunodeficiency virus infection
Around 4.87 million people are living with HIV in South, 
East and South-east Asia. The frequency of drug allergy/ 
hypersensitivity among patients with HIV infection ranges 
from 3-20% [64].
 Before the development of highly active anti-
retroviral therapies (HAART), the majority of drug allergies/ 
hypersensitivity were from antimicrobials used for the treatment 
or prophylaxis of opportunistic infections. These included 
TMP-SMX, sulfadiazine, dapsone, clindamycin, thiacetazine, 
aminopenicillins and atovaquone. Adverse reactions ranged 
from urticaria, maculopapular exanthems to fever, neutropenia, 
thrombocytopenia, nephritis, elevated liver enzymes, DiHS, SJS 
and TEN [65].
 
TMP-SMX is used in the treatment and prophylaxis of 
Pneumocystis jiroveci pneumonia and toxoplasmosis. 
Desensitization protocols have been shown to be useful in 
Cochrane metaanalyses [66], and protocols have been developed 
for use in both adults and children with TMP-SMX allergy. Oral 
TMP-SMX is usually used, with target doses initially attained within 
7 days in the earlier studies [67], subsequently reduced to 3-days 
[68] and 2-days [69] among adults, then to a 4-hour protocol in 
infants and children [70]. Where the initial reaction was SJS/TEN, 
desensitization has to be carefully discussed with the patient/
family as the risks of desensitization may outweigh the benefits 
[71]. SMX haptenation, but not SMX-specific antibodies, appear to 
be important in the development of clinical sensitivity (i.e. failure 
of desensitization) in patients with AIDS who have undergone 
SMX desensitization [14]. 
With the introduction of HAART in the 1990s, reports of 
hypersensitivity reactions to antiretroviral agents have increased. 
HAART drugs are classified as reverse transcriptase inhibitors 
(nucleoside [NRTI] and non-nucleoside reverse transcriptase 
inhibitors [NNRTI]), protease inhibitors (PI), fusion inhibitors, 
integrase inhibitors and entry inhibitors (CCR5 co-receptor 
antagonist). Single and various combination (fixed dose) drug 
therapies are currently available. While most of the anti-retroviral 
therapies have been associated with drug hypersensitivity/ allergy, 
abacavir (NRTI) and nevirapine (NNRTI) are particularly important 
as they are associated with potentially serious adverse reactions.
Abacavir hypersensitivity syndrome is usually multi-organ, 
potentially life-threatening reaction that occurs in both adults 
and children and approximately 5% to 8% of HIV-infected treated 
patients [72]. HLA-B5701 has been found to be associated with 
abacavir hypersensitivity among Caucasians [73] but not in non-
Caucasian populations [74]. Thus, the use of genetic screening 
prior to prescription of abacavir in Caucasians was the first 
clinical application of screening of at-risk individuals prior to drug 
prescription. This originated in Perth, Western Australia which was 
one of the study sites for the PREDICT-1 study [75].
Nevirapine hypersensitivity occurs in 13% [76], most commonly 
MPE, with severe cutaneous adverse reactions (SCAR) (including 
SJS/TEN) occurring in 0.5-1% [77, 78]. The various types of 
hypersensitivity/ allergy reaction with other anti-retroviral 
therapies has been comprehensively reviewed elsewhere [64].
Single case reports of successful desensitization protocols have 
been described for amprenavir [79], darunavir [79, 80], efavirenz 
[81], enfuvirtide [82, 83], nelfinavir [84] and zidovudine [85]. 
As is the case for TB drug allergy, one of the main challenges in 
HAART drug allergy is the identification of the putative drug: 
especially since standard therapy often involves 2 NRTIs plus a PI/
NNRTI/integrase inhibitor often in addition to antimicrobials for 
prevention or treatment of opportunistic infections.apallergy.org
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Allopurinol desensitization
Gout is known to be prevalent in the Asia-Pacific region, 
ranging from 0.2% in Thailand and Vietnam, to 4% among 
Australian aboriginals [86]. Severe tophaceous gout has been 
described among the Malayo-Polynesian and Malayo-Mongoloid 
communities in urban and rural North Sulawesi, Indonesia [87] 
and Maoris in New Zealand [88]. Gout is also associated with the 
metabolic syndrome among Koreans [89] and Japanese [90], 
and an important cause of all-cause and cardiovascular mortality 
among Taiwanese [91].
Allopurinol is a xanthine oxidase inhibitor which is commonly 
used in the treatment of gout and as prophylaxis against tumor 
lysis syndrome in the treatment of haematological malignancies. 
Although 2% of patients administered allopurinol may develop 
a mild MPE [92], SJS and TEN are not uncommon [77]. In Asia, 
HLA B*5801 has been found to be associated with allopurinol 
induced SJS/TEN in Han Chinese from studies in Taiwan [93], Thais 
[94], Japanese [95],
 and DiHS, SJS/TEN among Koreans [96, 97]. 
However, HLA-A*0201 was not found among Korean patients with 
SCAR despite relatively high frequency among tolerant controls, 
suggesting a negative association [97].
Allopurinol desensitization was first described by Meyrier in a 
patient with chronic renal disease [98]. Subsequent protocols 
using intraveneous [99] and oral [100]
 formulations have been 
shown to be generally safe and effective in the long-term 
[101]. Cutaneous eruptions are easily managed with temporary 
withdrawal and dose adjustment of allopurinol, even in individuals 
with renal impairment
 [101]. However, immediate hypersensitivity 
reactions can recur even after successful desensitization, hence 
the need for constant vigilance
 [102].
Febuxostat, a selective xanthine oxidase/ xanthine dehydrogenase 
inhibitor is an alternative treatment for patients who develop adverse 
reactions to allopurinol
 [103]. In the Asia Pacific region where this 
drug is presently not available, the alternatives for patients with 
allopurinol allergy who cannot undergo desensitization include 
[104, 105]:
•	 	 Probenecid, a uricosuric agent, provided renal function is not 
impaired and the patient does not have urate nephropathy,
•	 	 Benzbromarone, a uricosuric agent, which is only available 
in certain countries as it was withdrawn by its original 
manufacturer in 2003 after reports of serious hepatotoxicty,
•	 	 Rasburicase, a recombinant urate oxidase which is approved 
for the prevention and treatment of tumor lysis syndrome in 
patients receiving chemotherapy for hematologic cancers 
such as leukemias and lymphomas. Its use in gout remains 
investigational [106]. 
Desensitization to insulins for diabetes mellitus
The prevalence of diabetes mellitus in Asia Pacific countries 
ranges from 2.6% to 15.1%, with population attributable fractions 
ranging from 2% to 12% for coronary heart disease, 1% to 6% 
for haemorrhagic stroke, and 2% to 11% for ischaemic stroke 
[107].
 Despite the high prevalence of diabetes mellitus, drug 
allergy to oral hypoglycemic agents is fortunately uncommon. 
Case reports of patients with psoriasiform [108, 109] or lichenoid 
drug eruptions [110] to sulfonylureas and biguanide, purpuric 
dermatoses [111] and hepatitis [112] from sulfonylureas, drug-
induced hepatitis with thiozolidinediones [113], and angiotensin-
converting enzyme inhibitor angioedema precipitated by 
dipeptidyl peptidase-IV inhibitors [114] have been reported. 
Insulin allergy, in the form of localized or systemic reactions 
which may be immediate, delayed or serum sickness like, occurs 
in less than 1% of diabetic patients on insulin. It may be due to 
the insulin itself or its additives (zinc, protamine, cresol, phenol, 
glycerol). The causative agent can be determined by skin prick 
and intradermal tests to the insulin preparation, insulin additives; 
and in specialized centres, measurement of specific IgE or IgG 
levels to insulin. Insulin allergy is less common these days in view 
of the use of recombinant insulins
 [115]. Nonetheless, diagnostic 
skin testing and effective desensitization regimes have been 
well described
 [116]. From the Asia-Pacific region, successful 
desensitization using insulin glargine
 [117, 118], crystalline zinc 
insulin [119] and continuous insulin infusion [120] have been 
reported from Japan and various types of recombinant insulin 
from Korea [121-123]. Human insulin-specific antibody measured 
4, 8 and 12 weeks after successful desensitization in a 68-year-
old Korean man showed gradual decrease in human insulin 
specific IgE levels, and increase in IgG1, IgG2 and IgG4 over 
time [124]. Recurrence of systemic reaction following successful 
desensitization to human recombinant insulin has been described 
in a case report from Singapore
 [125].
ASA desensitization for coronary artery disease
The incidence of ASA hypersensitivity in the general population 
ranges from 0.6-2.5% [126, 127],
 but that in adult asthmatics 
ranges from 4.3-11% [128]. In the Asia-Pacific region, studies 
from Korea have demonstrated specific genetic and ethnic risk 
factors in Korean populations for AERD, AIU and AICU
 [129]. apallergy.org
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The true prevalence for ASA hypersensitivity among individuals 
with coronary artery disease in the Asia-Pacific region is 
unknown. Nonetheless, low-dose (81-325 mg/day), rapid ASA 
desensitization-challenge regimes appear to be useful in patients 
with ASA/NSAID sensitivity with coronary artery disease, in 
particular those who have undergone percutaneous coronary 
intervention [26, 130]. ASA desensitization is not desensitization 
in the truest sense of the word as the majority of ASA reactions 
are largely idiosyncratic with no immune mechanisms involved. 
The mechanisms are likely to be similar to high-dose ASA 
desensitization. The published protocols so far have been effective 
in the majority of patients studied
 [131-133], with relatively low 
rates of desensitization failure up to 24 months from initiation
 
[131].
 For ASA
 desensitization failures, alternative types of stents 
[134] or other anti-platelet combinations may need to be 
considered.
Chemotherapeutic and biologic agents
Cancer is a major cause of death in the Asia-Pacific with cancer 
frequencies and cancer types varying across different Asian 
countries. The incidence and prevalence of gastric cancer is high 
in East Asia and very low in the South East Asian countries. In 
contrast, hepatocellular carcinoma rates are high in the entire 
region in view of the endemicity of chronic hepatitis B infection
 
[135]. Chemotherapeutic agents that are most commonly 
associated with hypersensitivity reactions include platinum-
based drugs in the treatment of ovarian, small cell lung and germ 
cell cancer; taxanes and monoclonal antibodies (transtuzumab) 
used in the treatment of breast cancer; and rituximab in the 
treatment of non-Hodgkin’s lymphoma. These drugs are often 
needed for refractory or recurrent disease. Standardized 12-step 
desensitization protocols given intravenously/intraperitoneally 
over 6 h have been found to be safe and effective in 94% 
of infusions (mild or no reactions), with no life-threatening 
adverse reactions reported
 [136]. Among patients who received 
standardized 12-step desensitization protocols for transtuzumab, 
rituximab and infliximab, hypersensitivity reactions occurred 
during 29% of desensitizations, including 27 mild reactions, 
1 moderate reaction, and 2 severe reactions
 [137]. In these 
studies, the initial desensitizations were done in an intensive care 
setting, and subsequent infusions as outpatients. Breakthrough 
symptoms can be managed with anti-histamines and systemic 
glucocorticoids, and decelerating the dose escalation with 
intermediate infusion steps [5].
CONCLUSION
The objectives, indications, contraindications, principles of 
drawing up drug desensitization regimes are similar. However, 
the mechanisms of desensitization for immediate versus 
non-immediate reactions are clearly distinct. Most current 
desensitization regimes are effective and can be safely carry out 
with careful patient selection and close monitoring under the 
supervision of trained allergists and nursing staff.
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